+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cortisol responses to cholinergic drugs in Alzheimer's disease

Cortisol responses to cholinergic drugs in Alzheimer's disease

International Journal of Clinical Pharmacology, Therapy, and Toxicology 26(10): 471-476

Patients with Alzheimer's disease participated in a trial of two sessions in which they received physostigmine and neostigmine in a double-blind crossover disign. Most of these patients subsequently participated in a scopolamine vs saline double-blind crossover trial using a similar design. Physostigmine increased plasma cortisol relative to neostigmine, with the greatest difference at time points greater than 90 min post drug oral administration. Physostigmine also significantly decreased plasma cholinesterase (ChE). There was a significant positive correlation between the effects of physostigmine on increasing cortisol and decreasing ChE; there was no correlation between the increase in cortisol of cholinesterase inhibitor following neostigmine administration, but neither of these chemical parameters is related to the drug's effects on cognitive functioning.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 007165391

Download citation: RISBibTeXText

PMID: 3069749

Related references

Current development of antidementia drugs for Alzheimer disease Cholinergic drugs. Japanese Journal of Pharmacology 67(SUPPL 1): 57P, 1995

Cholinergic drugs in Alzheimer's disease. New England Journal of Medicine 315(20): 1286-1287, 1986

Treatment of Alzheimer's disease with cholinergic drugs. International Journal of Clinical Pharmacology, Therapy, and Toxicology 29(1): 23-37, 1991

Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Reviews in Medicinal Chemistry 2(1): 11-25, 2002

Optimal use of cholinergic drugs in Alzheimer's disease. Brain 141(9): E68, 2018

Treating Alzheimer's disease with cholinergic drugs, Part 2. Nurse Practitioner 24(1): 117-119, 1999

Recent advances in cholinergic drugs for Alzheimer's disease. Current Opinion in Drug Discovery and Development 2(4): 311-320, 1999

Treating Alzheimer's disease with cholinergic drugs, Part I. Nurse Practitioner 23(11): 90, 92, 97 Passim, 1998

Cholinergic and glutamatergic drugs in Alzheimer's disease therapy. Expert Review of Neurotherapeutics 5(5): 671-682, 2005

Individual responses of Alzheimer patients during treatment with the cholinergic drugs arecoline and physostigmine Kinetic, physiological, and cognitive measures. Society for Neuroscience Abstracts 22(1-3): 202, 1996

Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease?. Cns Neuroscience and Therapeutics 16(4): 235-245, 2010

The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis. Chemico-Biological Interactions 175(1-3): 204-208, 2008

The efficacy of cholinergic drugs in patients with Alzheimer's disease: Focus on aminoacridines. Human Psychopharmacology 10(2): 89-96, 1995

Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Molecular Pharmacology 66(3): 538-544, 2004

Non-cholinergic pharmacotherapy approaches to Alzheimer's disease: the use of non-steroidal anti-inflammatory drugs. Cns and Neurological Disorders Drug Targets 10(1): 133-139, 2011